| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Liming Yang | Q89259685 |
| P2093 | author name string | Rui Wang | |
| Hong Li | |||
| Yinghong Zheng | |||
| Ziyu Gao | |||
| Zhongni Liu | |||
| P2860 | cites work | Inhibition of Galectin-3 Alleviates Cigarette Smoke Extract-Induced Autophagy and Dysfunction in Endothelial Progenitor Cells | Q91317712 |
| Negative Risk Markers for Cardiovascular Events in the Elderly | Q91615599 | ||
| Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study | Q91895158 | ||
| [Myocardial Strain Properties in Patients with Chronic Heart Failure] | Q92517796 | ||
| Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway | Q92962373 | ||
| Prognostic biomarkers in acute coronary syndrome | Q26738521 | ||
| Galectin-3: its role in asthma and potential as an anti-inflammatory target | Q27023534 | ||
| Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells | Q28118886 | ||
| Intracellular functions of galectins | Q28201120 | ||
| Galectins. Structure and function of a large family of animal lectins | Q28246794 | ||
| Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
| Recent insights into the cellular biology of atherosclerosis | Q30300194 | ||
| Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study | Q33529398 | ||
| Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation. | Q33754984 | ||
| Secretion of the galectin family of mammalian carbohydrate-binding proteins | Q33783731 | ||
| Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice | Q33828006 | ||
| Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans | Q34122713 | ||
| Galectinomics: finding themes in complexity | Q34148905 | ||
| Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). | Q34269132 | ||
| Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis | Q34316944 | ||
| Galectins as modulators of tumour progression | Q34381235 | ||
| Galectin-3: an open-ended story | Q34494555 | ||
| Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction | Q34528187 | ||
| Galectin-3: a novel mediator of heart failure development and progression | Q34995162 | ||
| Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis | Q35026202 | ||
| Critical role of galectin-3 in phagocytosis by macrophages | Q35169042 | ||
| Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? | Q35286926 | ||
| Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community | Q35671472 | ||
| Progression of left ventricular diastolic dysfunction and risk of heart failure | Q35719757 | ||
| Galectin-3 expression in human atherosclerotic lesions. | Q35765442 | ||
| Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. | Q35798551 | ||
| Role of endothelial dysfunction in atherosclerosis | Q35806066 | ||
| Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. | Q35809897 | ||
| Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes | Q35842591 | ||
| Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells | Q36089958 | ||
| Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice | Q36357458 | ||
| New Regulatory Roles of Galectin-3 in High-Affinity IgE Receptor Signaling. | Q36811564 | ||
| Spatial and temporal expression, and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis | Q36844332 | ||
| Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors | Q37096426 | ||
| Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. | Q37183959 | ||
| Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation | Q37443866 | ||
| Association of galectin-3 with markers of myocardial function, atherosclerosis and vascular fibrosis in patients with rheumatoid arthritis | Q57796538 | ||
| Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways | Q58608459 | ||
| Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte Chemoattraction | Q62657999 | ||
| NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure | Q64282928 | ||
| The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins | Q73405607 | ||
| Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 | Q82644905 | ||
| Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension | Q84539872 | ||
| Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction | Q86135613 | ||
| Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus | Q87139750 | ||
| [Impact of plasma pro-B-type natriuretic peptide amino-terminal and galectin-3 levels on the predictive capacity of the LIPID Clinical Risk Scale in stable coronary disease] | Q87587551 | ||
| Galectin-3 exacerbates ox-LDL-mediated endothelial injury by inducing inflammation via integrin β1-RhoA-JNK signaling activation | Q90399605 | ||
| Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway | Q37516514 | ||
| Galectin-3-null mice display defective neutrophil clearance during acute inflammation | Q37629666 | ||
| Comprehensive review of the prognostic value of galectin-3 in heart failure | Q38177147 | ||
| The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure | Q38194209 | ||
| Galectin-3 but not galectin-1 induces mast cell death by oxidative stress and mitochondrial permeability transition | Q38293221 | ||
| Atherosclerosis - A matter of unresolved inflammation | Q38417380 | ||
| The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management | Q38551693 | ||
| Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure | Q38687046 | ||
| Galectin‑3 induces the phenotype transformation of human vascular smooth muscle cells via the canonical Wnt signaling | Q38845124 | ||
| Downregulating galectin-3 inhibits proinflammatory cytokine production by human monocyte-derived dendritic cells via RNA interference | Q38909319 | ||
| Vitexin alleviates ox-LDL-mediated endothelial injury by inducing autophagy via AMPK signaling activation | Q38910927 | ||
| Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice | Q39191329 | ||
| Lipopolysaccharide-induced gelatinase granule mobilization primes neutrophils for activation by galectin-3 and formylmethionyl-Leu-Phe | Q39518249 | ||
| Extracellular galectin-3 counteracts adhesion and exhibits chemoattraction in Helicobacter pylori-infected gastric cancer cells | Q39695000 | ||
| Regulation of alternative macrophage activation by galectin-3. | Q40016366 | ||
| Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia | Q40753134 | ||
| Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index | Q40765198 | ||
| Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study | Q40939847 | ||
| Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets | Q40944709 | ||
| Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. | Q41020090 | ||
| Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway | Q41241181 | ||
| Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways | Q42077799 | ||
| NADPH oxidase 4 protects against development of endothelial dysfunction and atherosclerosis in LDL receptor deficient mice | Q42284239 | ||
| Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. | Q43493519 | ||
| Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins | Q44466555 | ||
| Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells | Q44688770 | ||
| CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation | Q45107882 | ||
| The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction treated invasively | Q45129579 | ||
| Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils | Q46320323 | ||
| A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury | Q46461255 | ||
| Galectin-3 enhances avian H5N1 influenza A virus-induced pulmonary inflammation by promoting NLRP3 inflammasome activation. | Q47549239 | ||
| Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. | Q47649685 | ||
| Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update | Q47653100 | ||
| The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis | Q47703344 | ||
| Galectin-3 is associated with coronary plaque burden and obstructive sleep apnea syndrome severity | Q47768450 | ||
| Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. | Q47854367 | ||
| Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. | Q48024001 | ||
| Galectins: a family of animal beta-galactoside-binding lectins | Q48084852 | ||
| The fibrosis marker galectin-3 and outcome in the general population | Q48821773 | ||
| Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. | Q50804043 | ||
| Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. | Q51011747 | ||
| Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. | Q52139416 | ||
| Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. | Q53141520 | ||
| Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. | Q53205052 | ||
| Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? | Q53233664 | ||
| Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. | Q53630691 | ||
| Thiodigalactoside-Bovine Serum Albumin Conjugates as High-Potency Inhibitors of Galectin-3: An Outstanding Example of Multivalent Presentation of Small Molecule Inhibitors. | Q55379330 | ||
| Inflammation in atherosclerosis | Q57295305 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P304 | page(s) | 5284728 | |
| P577 | publication date | 2020-02-14 | |
| P1433 | published in | Journal of Immunology Research | Q26841936 |
| P1476 | title | Galectin-3 Is a Potential Mediator for Atherosclerosis | |
| P478 | volume | 2020 |
| Q99240850 | Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction | cites work | P2860 |
Search more.